DARA BioSciences Filing Shelf Registration Statement to Replace Expiring Registration Statement
25 mars 2011 16h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., March 25, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (the "Company") (Nasdaq:DARA) today announced that it has filed a universal shelf registration statement on Form S-3 with the...
DARA BioSciences is Selected by MDB Capital Group as a 2011 "Best & Brightest-Company to Watch"
23 févr. 2011 08h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Feb. 23, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a Raleigh, North Carolina biopharmaceutical drug development company, has been selected by MDB Capital Group as a...
DARA BioSciences to Present at The Wall Street Analyst Forum 22nd Annual Analyst Conference
17 févr. 2011 09h00 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Feb. 17, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a biopharmaceutical development company, will be presenting at The Wall Street Analyst Forum 22nd Annual Analyst...
Agile Companies Like DARA BioSciences Advance Research for New Diabetes Medicines as Incidence of Disease Relentlessly Increases
15 févr. 2011 09h00 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Feb. 15, 2011 (GLOBE NEWSWIRE) -- Despite years of efforts by the government and medical associations to educate the public about the dangers of diabetes and the need for a healthy...
Study Results for DARA Biosciences' Lead Drug for Neuropathic Pain, KRN5500, Selected for Presentation by the International Conference on Accelerating the Development of Enhanced Pain Treatments ("ADEPT")
01 févr. 2011 08h30 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Feb. 1, 2011 (GLOBE NEWSWIRE) -- The Company (Nasdaq:DARA) announced that the University of Rochester in concert with ADEPT has selected the study results from the KRN5500 Phase 2 study...
DARA Regains NASDAQ Stockholders' Equity Compliance
07 janv. 2011 08h30 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Jan. 7, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) today announced that, on January 5, 2011, NASDAQ notified the Company that it has regained compliance with the...
DARA BioSciences Announces Additional Details From Phase I Clinical Study of DB959 for the Treatment of Type 2 Diabetes
05 janv. 2011 17h00 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Jan. 5, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), provided additional details from the recently completed Phase I clinical study for DB959, its PPAR (peroxisome...
DARA Bioscience's Offering Oversubscribed
04 janv. 2011 08h30 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Jan. 4, 2011 (GLOBE NEWSWIRE) -- On December 28, 2010, DARA BioSciences, Inc. (the "Company") (Nasdaq:DARA) announced that it planned to raise up to $4 million through a registered...
DARA BioSciences, Inc. Prices Registered Securities Offering
29 déc. 2010 08h47 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Dec. 29, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company") has priced a public offering of up to 4800 units at a price of $1000 per unit to the public with...
DARA BioSciences to Raise Up to $4,000,000 Through Registered Public Offering
28 déc. 2010 17h29 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Dec. 28, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company") announced today that it has commenced a registered public offering of up to $4 million of units...